Research advances in the application of proprotein convertase subtilisin/kexin type 9 inhibitors in intracranial atherosclerotic stenosis
10.19845/j.cnki.zfysjjbzz.2025.0128
- VernacularTitle:PCSK9抑制剂在颅内动脉粥样硬化性狭窄中应用的研究进展
- Author:
Yaxin WU
1
,
2
;
Yaxuan SUN
1
,
2
Author Information
1. Department of Neurology, Shanxi People&rsquo
2. s Hospital, Shanxi Medical University, Taiyuan 030012, China
- Publication Type:Journal Article
- Keywords:
Intracranial atherosclerosis;
Lipid metabolism;
Proprotein convertase subtilisin/kexin type 9 inhibitor;
Evolocumab
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(7):664-668
- CountryChina
- Language:Chinese
-
Abstract:
Intracranial atherosclerotic stenosis （ICAS） is an important cause of stroke worldwide， and abnormalities in lipid metabolism are major risk factors for its development and progression. Statins as lipid-lowering drugs can stabilize atherosclerotic plaques and prevent their rupture， but approximately 60% of statin users fail to achieve the goal of low-density lipoprotein cholesterol （LDL-C） recommended in guidelines， and statins are associated with the adverse effects such as drug resistance and abnormal liver function. Numerous studies have confirmed that proprotein convertase subtilisin/kexin type 9 （PCSK9） inhibitors can significantly reduce the level of LDL-C and the incidence rate of atherosclerosis-associated cardiovascular and cerebrovascular events and stabilize or even reverse atherosclerotic plaques， but with limited application in ICAS. This article reviews the mechanism of action of PCSK9 inhibitors， their therapeutic efficacy in intracranial atherosclerotic stenosis， and related research advances.
- Full text:2025081208442637916PCSK9抑制剂在颅内动脉粥样硬化性狭窄中应用的研究进展.pdf
